Literature DB >> 21656525

Identification of high-risk stage II and stage III colorectal cancer by analysis of MMP-21 expression.

Tao Wu1, Yi Li, Xiaohong Liu, Jianguo Lu, Xianli He, Qing Wang, Jipeng Li, Xilin Du.   

Abstract

BACKGROUND: The expression of matrix metalloproteinase-21 (MMP-21) has been shown to be elevated in some solid tumor and thought to enhance tumor invasion and metastasis ability. In the present study, we investigated the expression of MMP-21 and its association with prognosis in stage II and III colorectal cancer.
METHODS: MMP-21 expression was investigated in 286 cases of colorectal cancer by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of MMP-21 expression with clinicopathological characters and overall survival of patients with stage II and III colorectal cancer.
RESULTS: MMP-21 expression was significantly higher in colorectal cancer, compared with that in normal epithelial tissue. And it also correlated with tumor invasion, lymph node metastasis, and distant metastasis of colorectal cancer. MMP-21 was also proved to be an independent prognostic factor in patients with stage II as well as stage III colorectal cancer. However, no correlations between MMP-21 expression and patients' age, sex, tumor location, or differentiation status were detected.
CONCLUSION: These results suggested the potential role of MMP-21 in the invasion and metastasis process of human colorectal cancer. It could also be a novel molecular marker to predict prognosis of patients with stage II and stage III colorectal cancer.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656525     DOI: 10.1002/jso.21970

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer.

Authors:  Tao Wu; Yi Li; Jianguo Lu; Qing Qiao; Guoqiang Bao; Nan Wang; Xianli He; Xilin Du
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

2.  A human laterality disorder caused by a homozygous deleterious mutation in MMP21.

Authors:  Zeev Perles; Sungjin Moon; Asaf Ta-Shma; Barak Yaacov; Ludmila Francescatto; Simon Edvardson; Azaria J J T Rein; Orly Elpeleg; Nicholas Katsanis
Journal:  J Med Genet       Date:  2015-10-01       Impact factor: 6.318

3.  Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients.

Authors:  Qinglin Hu; Chuanjing Yan; Chengfei Xu; Hai Yan; Lian Qing; Yanjun Pu; Zeyou He; Xiaojun Li
Journal:  Tumour Biol       Date:  2013-12-08

Review 4.  Biochemical and Biological Attributes of Matrix Metalloproteinases.

Authors:  Ning Cui; Min Hu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-03-22       Impact factor: 3.622

5.  Decreased miR-30b-5p expression by DNMT1 methylation regulation involved in gastric cancer metastasis.

Authors:  Fengchang Qiao; Kun Zhang; Pihai Gong; Ling Wang; Jiaojiao Hu; Sen Lu; Hong Fan
Journal:  Mol Biol Rep       Date:  2014-06-10       Impact factor: 2.316

Review 6.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

7.  Regulatory activity based risk model identifies survival of stage II and III colorectal carcinoma.

Authors:  Gang Liu; Chuanpeng Dong; Xing Wang; Guojun Hou; Yu Zheng; Huilin Xu; Xiaohui Zhan; Lei Liu
Journal:  Oncotarget       Date:  2017-09-28

Review 8.  Insights into the Role of Matrix Metalloproteinases in Precancerous Conditions and in Colorectal Cancer.

Authors:  Zahra Pezeshkian; Stefania Nobili; Noshad Peyravian; Bahador Shojaee; Haniye Nazari; Hiva Soleimani; Hamid Asadzadeh-Aghdaei; Maziar Ashrafian Bonab; Ehsan Nazemalhosseini-Mojarad; Enrico Mini
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.